A5043416120- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiovascular and exercise physiology
- Cardiac Health and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Potassium and Related Disorders
- Cardiac Imaging and Diagnostics
- Cardiac Structural Anomalies and Repair
- Medication Adherence and Compliance
- Cardiovascular Effects of Exercise
- Mechanical Circulatory Support Devices
- Diabetes Treatment and Management
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Blood Pressure and Hypertension Studies
- Pharmaceutical Practices and Patient Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Issues in Pregnancy
- Cardiac Arrhythmias and Treatments
- Transplantation: Methods and Outcomes
- Cardiac Arrest and Resuscitation
- Erythropoietin and Anemia Treatment
- Cardiac Valve Diseases and Treatments
- Heart Rate Variability and Autonomic Control
Thomas Jefferson University
2010-2025
Thomas Jefferson University Hospital
1999-2025
Central Michigan University
2019-2024
Center for Devices and Radiological Health
2013-2023
United States Food and Drug Administration
2013-2023
Wayne State University
2019-2023
Western University of Health Sciences
2022-2023
Clinical Research Institute
2008-2023
Philadelphia University
2000-2023
Massachusetts General Hospital
2012-2023
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
Background— Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than any other medical condition. With aging population, impact expected increase substantially. Methods Results— We estimated future costs by adapting a methodology developed American Association project epidemiology from 2012 2030 without double counting attributed comorbid conditions. The model assumes that prevalence...
<h3>Context</h3>Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of on clinical outcomes.<h3>Objective</h3>To test efficacy and safety among patients failure.<h3>Design, Setting, Patients</h3>Multicenter, randomized controlled trial 2331 failure reduced ejection fraction. Participants in Heart Failure: A Controlled Trial Investigating Outcomes Exercise...
T he purpose of this report is to provide revised standards and guidelines for the exercise testing training individuals who are free from clinical manifestations cardiovascular disease those with known disease.These intended physicians, nurses, physiologists, specialists, technologists, other healthcare professionals involved in these populations.This accord "Statement on Exercise" published by American Heart Association (AHA). 1 These a revision 1995 AHA that addressed issues training. 2An...
IS A SYNDROME characterized by dyspnea and fatigue; however, patients with heart failure often also experience diminished health status, including reductions in physical social functioning other dimensions of health-related quality life. 1,2harmacological device interventions disease management programs for have provided little or modest improvements healthrelated 3,4The extent to which exercise training addition optimal evidence-based therapy improves patients' status is unknown.
In patients with heart failure and reduced ejection fraction (HFrEF), treatment sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of on cardiac remodeling is uncertain.To determine whether NT-proBNP changes in HFrEF treated correlate measures volume function.Prospective, 12-month, single-group, open-label study enrolled 78 outpatient sites the United States. Sacubitril-valsartan was initiated dose adjusted. Enrollment commenced...
HomeCirculationVol. 102, No. 9Core Components of Cardiac Rehabilitation/Secondary Prevention Programs
Background— The prognostic value of serum sodium in patients hospitalized for worsening heart failure has not been well defined. Methods and Results— Outcomes a Prospective Trial Intravenous Milrinone Exacerbations Chronic Heart Failure (OPTIME-CHF) study randomized 949 with systolic dysfunction to receive 48 72 hours intravenous milrinone or placebo addition standard therapy. In retrospective analysis, we investigated the relationship between admission primary end point days cardiovascular...
<h3>Importance</h3> The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on peptide levels ("guided therapy") with inconsistent results. <h3>Objective</h3> To determine whether an amino-terminal pro–B-type (NT-proBNP)–guided treatment strategy improves clinical outcomes vs usual care in high-risk patients reduced ejection fraction (HFrEF). <h3>Design, Settings,...
<h3>Background</h3> Mild hyponatremia is relatively common in patients hospitalized with heart failure (HF). To our knowledge, the association of outcomes has not been evaluated context in-hospital clinical course including central hemodynamics and changes serum sodium level. <h3>Methods</h3> The ESCAPE trial (Evaluation Study Congestive Heart Failure Pulmonary Artery Catheterization Effectiveness) was a randomized, controlled study designed to evaluate utility pulmonary artery catheter plus...